Apraglutide: The Once-Weekly GLP-2 Peptide for Short Bowel Syndrome — and Why the FDA Wants One More Trial (June 30, 2026)
Table of Contents
Another gut peptide, an even longer reach
A few days ago we covered glepaglutide, a long-acting GLP-2 analog for short bowel syndrome. Apraglutide is its closest cousin — and it pushes the same idea one step further on dosing. GLP-2 is the hormone the intestine releases after eating to grow and maintain its absorptive lining. Apraglutide (FE 203799), developed by Ironwood Pharmaceuticals, is a synthetic GLP-2 analog engineered for short bowel syndrome with intestinal failure (SBS-IF), where people who have lost much of their small intestine cannot absorb enough nutrition and depend on intravenous (parenteral) feeding.
Why once-weekly is the headline
What sets apraglutide apart is how rarely it needs to be injected. A four-amino-acid substitution in the natural GLP-2 sequence makes it resistant to the DPP-4 enzyme that normally chews up the hormone and increases how tightly it binds to blood proteins. The result is a half-life of about 72 hours — long enough for once-weekly subcutaneous dosing. For comparison, the first approved GLP-2 drug, teduglutide (Gattex/Revestive), has a half-life of only a few hours and must be injected every day; glepaglutide sits in between at twice weekly. For patients already managing nightly IV nutrition, fewer injections is a real quality-of-life difference.
How it works
Apraglutide is a GLP-2 receptor agonist. By switching on GLP-2 receptors in the bowel, it prompts the intestinal lining to grow taller villi and more absorptive surface, increases blood flow to the gut, and slows transit so there is more time to absorb fluid and nutrients. The goal is the same as every short bowel therapy: get the remaining intestine to absorb more, so patients can cut back — or eliminate — their IV support.
The evidence: the STARS trial
In the pivotal Phase 3 STARS trial, 164 adults with SBS-IF were randomized 2:1 to once-weekly apraglutide or placebo, grouped by intestinal anatomy (stoma versus colon-in-continuity). Apraglutide cut weekly parenteral support volume by about 25.5% at 24 weeks, versus 12.5% on placebo. The effect was especially strong in patients with colon-in-continuity — the group whose remaining colon can respond most to GLP-2. And across the long-term extension, 27 apraglutide-treated patients reached enteral autonomy, meaning they no longer needed parenteral support at all.
The catch: the FDA wants one more trial
Despite the positive trial, the path to market hit a wall. In April 2025 the FDA told Ironwood that it would need a confirmatory Phase 3 trial before approval, after concern that the drug exposure actually delivered in STARS was lower than intended because of how the dose was prepared and administered. The agency said STARS data would remain an integral part of the eventual application, and Ironwood planned to begin the new trial in 2026 — but also acknowledged it was weighing strategic options for the program. So as of mid-2026, apraglutide is not approved: it has strong Phase 3 data and a clear mechanism, but a confirmatory study stands between it and the clinic.
Where it fits — and the honest caveats
Apraglutide rounds out a small but real class of intestinotrophic GLP-2 peptides: daily teduglutide (approved), twice-weekly glepaglutide (under EU review, FDA wants more data), and once-weekly apraglutide (FDA wants a confirmatory trial). All of them stimulate gut tissue to grow, which is exactly the point in short bowel syndrome but also the reason they require monitoring for intestinal polyps and careful attention to the gallbladder, pancreas and fluid balance. Two caveats belong on any 2026 write-up: this is an investigational, prescription-only drug for a specific rare disease under specialist care — not a wellness compound and not something sold legitimately by 'research peptide' vendors — and it is not approved, with its U.S. future riding on one more trial.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Efficacy and Safety of Once-Weekly Apraglutide in SBS-IF: Phase 3 STARS Study — Intestinal Failure journal Source
- [2] Ironwood Provides Clinical and Regulatory Update on Apraglutide (FDA requires confirmatory Phase 3) — April 2025 Source
- [3] Ironwood rethinks options after FDA demands another phase 3 trial — Fierce Biotech Source
- [4] Apraglutide once-weekly GLP-2 analog improves intestinal absorption — Phase 1/2 metabolic balance trial (PMC) Source
Related Articles
Setmelanotide (Imcivree): The MC4R Peptide That Treats Obesity the GLP-1 Drugs Can't (June 26, 2026)
Setmelanotide (Imcivree) is a cyclic octapeptide that activates the brain's MC4R appetite switch directly — treating rare genetic and post-tumor hypothalamic obesity that GLP-1 drugs were never designed for. In March 2026 the FDA expanded it to acquired hypothalamic obesity, making it the first and only approved therapy for that condition.
Zosurabalpin (RG6006): The First-in-Class Macrocyclic Peptide Antibiotic Taking on a Critical Superbug (June 27, 2026)
Zosurabalpin (RG6006) is the first antibiotic of a brand-new structural class in decades — a tethered macrocyclic peptide that kills carbapenem-resistant Acinetobacter baumannii by jamming the bacterium's LPS transporter. Here's how it works and why its move into Phase 3 matters.
Glepaglutide: The Long-Acting GLP-2 Peptide Trying to Free Short Bowel Patients From IV Nutrition (June 30, 2026)
Glepaglutide is a long-acting GLP-2 analog dosed once or twice weekly that helps the remaining gut absorb more nutrients in short bowel syndrome — cutting, and sometimes eliminating, the need for IV nutrition. Here is where it stands in 2026 after positive Phase 3 data, an FDA Complete Response Letter, and a European filing.